Neurosense Therapeutics

NRSN · NASDAQ

$2.39−$0.275 (−10.32%)TodayMarket closed · Oct 20, 7:56 PM ET

Prev close $2.67

Latest news

NewsOct 19, 1:05 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
Press releaseOct 19, 8:25 AM ETPRNewswire
NeuroSense Files U.S. Patent Application for Traumatic Brain Injury
Press releaseOct 13, 8:30 AM ETPRNewswire
NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
Press releaseOct 2, 4:15 PM ETPRNewswire
NeuroSense Provides Update on Nasdaq Listing Compliance
Press releaseSep 28, 12:43 PM ETPRNewswire
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
Press releaseSep 25, 4:30 PM ETPRNewswire
NeuroSense Provides Business Update and Progress for the First Half of 2026
Press releaseSep 10, 9:00 AM ETPRNewswire
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
NewsSep 9, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsSep 4, 1:06 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsAug 31, 8:48 AM ET
NeuroSense Announces Redesigned Development Plan For PrimeC In Amyotrophic Lateral Sclerosis, Structured To Reach Potential Path For Regulatory Submission And Faster Approval
Press releaseAug 31, 8:45 AM ETPRNewswire
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
NewsAug 25, 5:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseAug 13, 9:30 AM ETPRNewswire
NeuroSense Issues CEO Letter to Shareholders
Press releaseAug 6, 11:29 AM ETPRNewswire
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
NewsJul 28, 5:01 AM ETAvi Kapoor
Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
NewsJul 22, 8:38 AM ET
NeuroSense Intends To Proceed With Filing Of NDS To Health Canada For PrimeC For Treatment Of Amyotrophic Lateral Sclerosis, Following Constructive Pre-NDS Meeting
Press releaseJul 22, 8:30 AM ETPRNewswire
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
Press releaseJul 6, 8:45 AM ETPRNewswire
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
Press releaseJun 29, 9:30 AM ETPRNewswire
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
Press releaseJun 25, 9:20 AM ETPRNewswire
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
Press releaseJun 22, 9:00 AM ETPRNewswire
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
NewsJun 17, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseJun 11, 9:00 AM ETPRNewswire
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
Press releaseJun 9, 9:00 AM ETPRNewswire
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
Press releaseApr 28, 2:30 PM ETPRNewswire
NeuroSense Announces Pricing of Insider-Led PIPE Financing
Press releaseApr 6, 9:20 AM ETPRNewswire
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
Press releaseApr 3, 10:02 AM ETPRNewswire
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
Press releaseMar 31, 9:20 AM ETPRNewswire
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
Press releaseMar 24, 9:00 AM ETPRNewswire
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
Press releaseMar 18, 8:00 AM ETPRNewswire
/C O R R E C T I O N -- NeuroSense/
Press releaseMar 18, 8:00 AM ETPRNewswire
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference
Press releaseMar 16, 11:33 AM ETPRNewswire
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
Press releaseMar 9, 11:07 AM ETPRNewswire
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
NewsFeb 18, 12:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsNov 24, 9:59 AM ET
FDA Completes Review Of IND Amendment Application And Authorizes NeuroSense To Initiate Pivotal Phase 3 Clinical Trial For Evaluation Of PrimeC, For ALS Treatment
NewsMay 12, 3:08 PM ETVandana Singh
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights
NewsOct 28, 8:00 AM ETVandana Singh
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission
NewsAug 28, 7:00 AM ETVandana Singh
EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

12 Health Care Stocks Moving In Monday's Intraday Session

NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

NeuroSense Provides Update on Nasdaq Listing Compliance

NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

NeuroSense Provides Business Update and Progress for the First Half of 2026

NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Friday's Intraday Session

NeuroSense Announces Redesigned Development Plan For PrimeC In Amyotrophic Lateral Sclerosis, Structured To Reach Potential Path For Regulatory Submission And Faster Approval

NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS

12 Health Care Stocks Moving In Tuesday's After-Market Session

NeuroSense Issues CEO Letter to Shareholders

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

NeuroSense Intends To Proceed With Filing Of NDS To Health Canada For PrimeC For Treatment Of Amyotrophic Lateral Sclerosis, Following Constructive Pre-NDS Meeting

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

12 Health Care Stocks Moving In Wednesday's After-Market Session

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

NeuroSense Announces Pricing of Insider-Led PIPE Financing

NeuroSense Granted Brazilian Patent Covering PrimeC Composition

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

/C O R R E C T I O N -- NeuroSense/

PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

12 Health Care Stocks Moving In Wednesday's Intraday Session

FDA Completes Review Of IND Amendment Application And Authorizes NeuroSense To Initiate Pivotal Phase 3 Clinical Trial For Evaluation Of PrimeC, For ALS Treatment

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission

EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug